MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
20 Fevereiro 2025 - 9:00AM
Business Wire
Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or
"MindMed"), a late-stage clinical biopharmaceutical company
developing novel product candidates to treat brain health
disorders, today announced that it will host a live webcast at 8:00
a.m. ET on Thursday, March 6, 2025 to report financial results for
the fourth quarter and year ended December 31, 2024, and discuss
recent business updates.
Listeners can register for the webcast via this link. Analysts
wishing to participate in the question and answer session should
use this link. A replay of the webcast will be available via the
Investor Relations section of the MindMed website, ir.mindmed.co,
and archived for at least 30 days after the webcast. Those who plan
on participating are advised to join 15 minutes prior to the start
time.
About MindMed
MindMed is a late-stage clinical biopharmaceutical company
developing novel product candidates to treat brain health
disorders. Our mission is to be the global leader in the
development and delivery of treatments that unlock new
opportunities to improve patient outcomes. We are developing a
pipeline of innovative product candidates, with and without acute
perceptual effects, targeting neurotransmitter pathways that play
key roles in brain health. MindMed trades on Nasdaq under the
symbol MNMD.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250220848926/en/
For Media: media@mindmed.co For Investors:
ir@mindmed.co
Mind Medicine MindMed (NASDAQ:MNMD)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Mind Medicine MindMed (NASDAQ:MNMD)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
